HC Wainwright Analysts Lift Earnings Estimates for PolyPid

PolyPid Ltd. (NASDAQ:PYPD) – Equities research analysts at HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for shares of PolyPid in a report issued on Thursday, May 14th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of ($0.38) per share for the quarter, up from their previous estimate of ($0.47). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.37) per share. HC Wainwright also issued estimates for PolyPid’s Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.52) EPS, FY2026 earnings at ($1.64) EPS, FY2027 earnings at ($0.71) EPS and FY2028 earnings at $0.10 EPS.

Other analysts have also issued research reports about the company. Weiss Ratings lowered PolyPid from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.25.

PolyPid Stock Up 6.1%

Shares of NASDAQ PYPD opened at $4.73 on Tuesday. The business’s 50 day moving average is $4.40 and its two-hundred day moving average is $4.25. The company has a market cap of $90.25 million, a P/E ratio of -2.48 and a beta of 1.41. PolyPid has a 12 month low of $2.44 and a 12 month high of $5.12.

PolyPid (NASDAQ:PYPD) last posted its earnings results on Wednesday, May 13th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.12.

Institutional Investors Weigh In On PolyPid

Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets increased its holdings in shares of PolyPid by 56.1% in the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after acquiring an additional 3,500 shares in the last quarter. HighTower Advisors LLC acquired a new position in shares of PolyPid during the fourth quarter worth about $44,000. Jane Street Group LLC acquired a new position in shares of PolyPid during the fourth quarter worth about $66,000. Renaissance Technologies LLC acquired a new position in shares of PolyPid during the first quarter worth about $81,000. Finally, XTX Topco Ltd boosted its position in shares of PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after buying an additional 10,888 shares during the period. 26.47% of the stock is currently owned by institutional investors.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.